Correction: 2016 American college of rheumatology/European league against rheumatism criteria for minimal moderate, and major clinical response in juvenile dermatomyositis (Annals of the Rheumatic Diseases (2017) 76 (782-791) DOI: 10.1136/annrheumdis-2017-211401);2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative

Annals of the Rheumatic Diseases

Volumn 76, Issue 5, 2017, Pages 782-791

  Rider, Lisa G ^a   Aggarwal, Rohit ^b   Pistorio, Angela ^c   Bayat, Nastaran ^a   Erman, Brian ^d   Feldman, Brian M ^e   Huber, Adam M ^f   Cimaz, Rolando ^g   Cuttica, Rubén J ^h   De Oliveira, Sheila Knupp ⁱ   Lindsley, Carol B ^j   Pilkington, Clarissa A ^k   Punaro, Marilynn ^l   Ravelli, Angelo ^m   Reed, Ann M ⁿ   Rouster Stevens, Kelly ^o   Van Royen Kerkhof, Annet ^p   Dressler, Frank ^q   Magalhaes, Claudia Saad ^r   Constantin, Tamás ^s   Davidson, Joyce E ^t,u   Magnusson, Bo ^v   Russo, Ricardo ^w   Villa, Luca ^c   Rinaldi, Mariangela ^c   Rockette, Howard ^b   Lachenbruch, Peter A ^a   Miller, Frederick W ^a   Vencovsky, Jiri ^x   Ruperto, Nicolino ^c   more..

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c G GASLINI INSTITUTE   (Italy)

^d SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f IWK HEALTH CENTRE   (Canada)

^g UNIVERSITY OF FLORENCE   (Italy)

^h UNIVERSIDAD DE BUENOS AIRES   (Argentina)

ⁱ FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^j UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^k GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ DUKE UNIVERSITY   (United States)

^o EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^q HANNOVER MEDICAL SCHOOL   (Germany)

^r SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^s SEMMELWEIS UNIVERSITY   (Hungary)

^t ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^u ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^v KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^w HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^x CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; CHILD; CONSENSUS; CONSENSUS DEVELOPMENT; DERMATOMYOSITIS; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STANDARDS; VALIDATION STUDY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CONSENSUS; DERMATOMYOSITIS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 85019114552     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211401corr1     Document Type: Erratum

References (38)

1. Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S118-57.
2. Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40:1262-73.
3. Rider LG, Giannini EH, Harris-Love M, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-17.
4. Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003;42:1452-9.
5. Ruperto N, Ravelli A, Pistorio A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease Activity Core Set for the Evaluation of Response to Therapy in Juvenile Dermatomyositis: a prospective validation study. Arthritis Rheum 2008;59:4-13.
6. Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011;96:596-601.
7. Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
8. Bode RK, Klein-Gitelman MS, Miller ML, et al. Disease Activity Score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003;49:7-15.
9. Rider LG, Giannini EH, Brunner HI, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90.
10. Ruperto N, Pistorio A, Ravelli A, et al. The Paediatric Rheumatology International Trials Organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010;62:1533-41.
11. Hasija R, Pistorio A, Ravelli A, et al. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum 2011;63:3142-52.
12. Ruperto N, Pistorio A, Ravelli A, et al. Criteria to define response to therapy in paediatric rheumatic diseases. Eur J Clin Pharmacol 2011;67(Suppl 1):125-31.
13. Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 2016;387:671-8.
14. Felson DT, Furst DE, Boers M. Rationale and strategies for reevaluating the ACR20. J Rheumatol 2007;34:1184-7.
15. Rider LG, Ruperto N, Pistorio A, et al. 2016 development of adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria: methodological aspects: an American College of Rheumatology/European League Against Rheumatism/International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Rheumatology (Oxford) 2016. In press.
16. Rider LG, Aggarwal R, Bayat N, et al. A hybrid conjoint analysis model is proposed as the definition of minimal, moderate and major clinical improvement in juvenile dermatomyositis clinical trials. J Rheumatol 2014;66(Suppl):S578.
17. Aggarwal R, Rider LG, Ruperto N, et al. A consensus hybrid definition using a conjoint analysis is the proposed response criteria for minimal and moderate improvement for adult polymyositis and dermatomyositis clinical trials. Arthritis Rheumatol 2014;66(Suppl):S404.
18. Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology/European League AGainst Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis Rheumatol. Published Online First.
19. Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2015;67:2557-68.
20. Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord 2014;7:263-75.
21. Amaya-Amaya M, Gerard K, Ryan M. Discrete choice experiments in a nutshell. In: Ryan M, Gerard K, Amaya-Amaya M, eds. Using discrete choice experiments to value health and health care. Dordrecht: Springer; 2008.
22. De Bekker-Grob E, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ 2012;21:145-72.
23. De Lautour H, Taylor WJ, Adebajo A, et al. Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises. Arthritis Care Res (Hoboken) 2016;68:667-72.
24. Hansen P, Ombler F. A new method for scoring additive multi-attribute value models using pairwise rankings of alternatives. J Multi-Crit Decis Anal 2008;15:87-107.
25. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
26. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
27. Finney DJ. Statistical method in biological assay. 3rd edn. London: Charles Griffin, 1978.
28. Liengme BV. A guide to Microsoft Excel 2002 for scientists and engineers. 3rd edn. Oxford: Butterworth-Heinemann, 2002.
29. Ruperto N, Meiorin S, Iusan SM, et al. Consensus procedures and their role in pediatric rheumatology. Curr Rheumatol Rep 2008;10:142-6.
30. Delbecq A, van de Ven A, Gustafson D. Group techniques for program planning: a guide to nominal group and Delphi processes. Glenview, IL: Scott, Foresman and Company, 1975.
31. Ruperto N, Ozen S, Pistorio A, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: overall methodology and clinical characterisation. Ann Rheum Dis 2010;69:790-7.
32. Piram M, Kone-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 2014;73:2168-73.
33. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007;57:193-202.
34. Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry 2002;47:262-6.
35. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
36. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
37. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658-66.
38. Volochayev R, Csako G, Wesley R, et al. Laboratory test abnormalities are common in polymyositis and dermatomyositis and differ among clinical and demographic groups. Open Rheumatol J 2012;6:54-63.